Cardinal Health Inc. (CAH)

Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.

Cardinal (CAH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

CAH is set to buy Solaris Health for $2.4B, boosting urology presence with 750+ providers and expanding Specialty Alliance reach.

The heavy selling pressure might have exhausted for Cardinal (CAH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy...

Sprawling healthcare company Cardinal Health (CAH -7.08%) reported its latest quarterly results and announced a sizable new acquisition Tuesday morning. The market didn't take these news items well, h...

While the top- and bottom-line numbers for Cardinal (CAH) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to...

Cardinal Health (CAH) came out with quarterly earnings of $2.08 per share, beating the Zacks Consensus Estimate of $2.03 per share. This compares to earnings of $1.84 per share a year ago.

Cardinal Health's multi-specialty management services organization (MSO), The Specialty Alliance, plans to acquire urology MSO Solaris Health. Cardinal Health will enable the acquisition by providing ...